Concepedia

Tesfaye Liranso

TL

Statistics

Publications

10

Citations

386

H-Index

10

Active since

2019

Affiliations

Supernus Pharmaceuticals (United States)(Current)

SUNY Upstate Medical University

Virginia Commonwealth University

Massachusetts General Hospital

Neuroscience Education Institute

Tesfaye Liranso is an author at Supernus Pharmaceuticals (United States) specializing in pediatrics, adhd, and mood disorders.

Top concepts

Publications per year

2019–2022

10

Publications

10

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2020 · 81 citations · Full text

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Janet Johnson, Tesfaye Liranso, Keith E. Saylor et al. · Journal of Attention Disorders · 2019 · 60 citations · Full text

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2021 · 53 citations

, , +11

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

Azmi Nasser, Joseph T. Hull, Soumya A. Chaturvedi et al. · CNS Drugs · 2022 · 49 citations · Full text

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Journal of Clinical Psychopharmacology · 2021 · 40 citations · Full text

1–5 of 10